‘Report Predicts Multiple Sclerosis Drug Market Will Reach $15.8bn in 2015′ Says visiongain Report

By Visiongain, PRNE
Thursday, November 24, 2011

LONDON, November 25, 2011 -


A new report by visiongain predicts that revenues for disease-modifying treatments for multiple sclerosis (MS) will rise to $15.8bn annually in 2015. That analysis appears in Multiple Sclerosis Treatment: World Drug Market 2012-2022, published in November 2011. Visiongain is a business information provider based in London, UK.

Visiongain forecasts that the MS drug industry and market will expand to 2015. There will be strong revenue growth in established and developing pharmaceutical markets, especially the US, Japan and the UK. The MS treatment market will change with the launch of new agents that slow symptom progression and reduce relapse rates.

John O’Neill, a pharmaceutical industry analyst at visiongain, said: “Entry of more-efficacious treatments to the MS drug market - and drugs that can be taken orally rather than injected - will expand the treated patient population. There is scope for important developments in national markets such as the UK, where the number of MS patients is high and treatment can be improved.”

In particular, this new study predicts the future of the drugs Copaxone, Avonex, Rebif, Betaseron/Betaferon, Tysabri, Extavia and Gilenya, showing revenue forecasts to 2022. The report discusses companies such as Biogen Idec, Teva, Sanofi, Novartis, Merck Serono and Bayer. It also assesses the R&D pipeline for treating multiple sclerosis and forecasts leading national markets.

With a strong R&D pipeline, the MS treatment market will expand this decade. Products from its pipeline will help patients, as will extensions of the indication ranges for marketed drugs. Multiple Sclerosis Treatment: World Drug Market 2012-2022 adds to visiongain’s range of analytical research reports on immune disorders, neurodegenerative disorders and other therapeutic areas.

To see report sample pages please click on:


Table of Contents

Executive Summary
1.1 Multiple Sclerosis: Treatment Market Overview
1.2 Chapter Breakdown
1.3 Research and Analysis Methods

2. Introduction to Multiple Sclerosis and its Treatment
2.1 The Pathology of Multiple Sclerosis
2.2 Diagnosis of MS
2.3 Measuring MS
2.4 The Different Types of Multiple Sclerosis
2.4.1 Relapsing Remitting MS
2.4.2 Secondary Progressive MS
2.4.3 Progressive Relapsing MS
2.4.4 Primary Progressive MS
2.4.5 Other Presentations of the Disease
2.5 Possible Causational Factors for MS
2.5.1 Genetic Factors
2.5.2 Infection
2.5.3 Environmental Factors and Less Well-Supported Theories
2.6 Demographics and Geographical Distribution
2.7 Economic Costs
2.8 Treatment Options
2.8.1 Treatment of Symptoms
2.8.2 Treatment of Attacks
2.8.3 Treatment of Disease Progression (Disease-Modifying Treatments)
2.8.4 Other Drugs and Off-Label Treatments Rituxan (Rituximab, MabThera) Campath (Alemtuzumab) Novantrone (Mitoxantrone) Imuran (Azothioprene) Cyclophosphamide Intravenous Immunoglobulin (IVIg) Methotrexate (Maxtrex) Low-Dose Naltrexone
2.8.5 Alternative Treatments

3. The World Market for MS Drugs, 2011-2022
3.1 The MS Market in 2010
3.2 Copaxone Led the MS Drug Market in 2010
3.3 Together, Interferons Form Over Half the Market
3.4 Market Forecast, 2010-2022
3.4.1 The Impact of New Drugs on the MS Market
3.4.2 The Impact of Generic Drugs on the MS Market

4. Leading National Markets for MS Drugs, 2011-2022
4.1 MS Drug Sales and Market Shares in Leading National Markets, 2010
4.2 Leading MS Markets: Sales Forecasts, 2011-2022
4.3 The US Is the Largest Market for MS Drugs
4.4 Europe
4.4.1 Germany Has the Largest EU Market for MS Drugs
4.4.2 France
4.4.3 Spain
4.4.4 Italy
4.4.5 The UK
4.5 Japan
4.6 India
4.7 China

5. Drugs for Treating MS: Sales Prospects, 2011-2022
5.1 Copaxone
5.1.1 Copaxone Sales Forecast 2011-2022
5.1.2 Copaxone Will Benefit from Label Extension
5.2 Threat from Generic Competition for Copaxone
5.3 Avonex
5.3.1 Method of Use Patent Extension to 2026
5.3.2 PEG-Avonex
5.4 Rebif
5.5 Betaseron/Betaferon
5.6 Tysabri
5.6.1 PML and the JCV Assay
5.7 Extavia
5.8 Gilenya
5.8.1 Quarter-on-Quarter Growth of Gilenya
5.9 Biosimilars

6. Leading Companies in the MS Drug Industry
6.1 Biogen Idec
6.1.1 Biogen Idec’s Strong MS Pipeline
6.1.2 Biogen Has Licensed Ampyra, a Novel Treatment for MS Symptoms
6.1.3 The Threat of Biosimilars
6.2 Teva and Sanofi
6.2.1 Threats to Copaxone Generic Competition for Copaxone BG-12 Pipeline Copolymers
6.2.2 Opportunities for Copaxone
6.2.3 Extending Teva’s MS Drug Franchise
6.3 Novartis
6.4 Merck Serono
6.5 Bayer

7. The R&D Pipeline for Disease-Modifying MS Treatment
7.1 MS Pipeline Drugs
7.2 Fast Forward
7.3 Modifications of Existing Drugs
7.3.1 PEG-INF (PEGylated Interferon Beta-1a)
7.3.2 NU100 (Interferon beta-1b) and NU400 (PEGylated Interferon Beta-1b)
7.3.3 Adjunct Therapies
7.4 Drugs that Regulate the Immune Response
7.4.1 Aubagio (Teriflunomide)
7.4.2 Laquinimod
7.4.3 Zanapax (Daclizumab)
7.4.4 Lemtrada/Campath (Alemtuzumab)
7.4.5 Oreclizumab
7.4.6 Trimesta
7.4.7 PI-2301
7.5 Anti-Inflammatory Drugs
7.5.1 BG-12 (Dimethyl Fumarate)
7.6 Drugs that Promote Remyelination
7.6.1 Olexisome
7.7 Vaccine Therapies
7.7.1 Tovaxin
7.7.2 BHT-3009
7.8 Stem Cell Treatment
7.9 Sativex
7.10 There is Strong Potential in the MS Drug Pipeline

8. Factors that Influence the MS Drug Industry and Market
8.1 SWOT Analysis
8.2 Market Drivers
8.2.1 The MS Market Has Opportunities for Continuing Growth
8.2.2 Labelling Extensions for New Indications Can Drive Uptake
8.2.3 Competition Between Older and Newer Products
8.2.4 Other Services
8.2.5 Drug Preference
8.2.6 Advances in Technology Will Benefit Patients and the Market Targeting Patient Subpopulations
8.2.7 The Rise of Comparative Studies
8.3 Market Restraints
8.3.1 The Threat of Generics and Biosimilars (Follow-on Biologics)
8.3.2 Cost Concerns
8.3.3 Off-Label Use and Risk-Sharing Schemes
8.3.4 Side Effects and Treatment Compliance

9. Research Interviews
9.1 Interview with Dr Karen M. Stockl (Prescription Solutions)
9.1.1 Improving Self-Management of MS
9.1.2 The Impact and Benefits of DTM Programmes
9.1.3 Improving Medication Adherence in MS Patients
9.1.4 Impact of Oral MS Medications
9.2 Interview with Dr Johan Luthman (Merck Serono)
9.2.1 On Understanding the Disease and its Treatments
9.2.2 On Unmet Needs for Treatment
9.2.3 On Current Treatment Options
9.2.4 On Medical Marijuana Use
9.2.5 On Oral Drugs
9.2.6 On Future Treatment Possibilities
9.3 Second Interview with Dr Johan Luthman (Merck Serono), Specifically Concerning Stem Cell Potential
9.3.1 On Stem Cell Media Coverage
9.3.2 On the Therapeutic and Curative Potential of Stem Cells for Neurological Disorders
9.3.3 On the Treatment of Neurological Disorders
9.3.4 On Stem Cell Treatment of MS: Viability, Curative Power, Treatment Strategy and Results
9.3.5 On the Time Frame for Marketable Stem Cell Treatment Options

10. Conclusions from the Study
10.1 Growth of the MS Market Will Continue, But Will Be Limited by Competition
10.2 There Will Be Continued Growth in Leading Markets, Owing to New Products and Expanding Treatment Populations
10.3 There is a Strong R&D Pipeline for MS Treatment
10.4 Leading Companies in the MS Drug Market
10.5 Market Drivers
10.6 Market Restraints
10.7 Prospects for the MS Drug Market - Concluding Thoughts

Companies Listed

AB Science SA
Abbott Laboratories
Acorda Therapeutics
Active Biotech
Artielle Immunotherapeutics
Baxter Healthcare Corporation
Bayer Schering
Bayhill Therapeutics
Biogen Idec
BioMS Medical Corp
Canbex Therapeutics
Cell Therapeutics
CenTRion Therapeutics
Charite University
Chromos Molecular Systems
Clinical Data
Daiichi Sankyo
Duke University
Elan Pharmaceuticals
European Medicines Agency (EMA)
Fast Forward
FivePrime Therapeutics
Food and Drug Administration (FDA, US)
GlaxoSmithKline (GSK)
Glenmark Pharmaceuticals
GTC Biotherapeutics
GW Pharmaceuticals
Hard to Treat Diseases (HTDS)
Hemispherx Biopharma
Henry Ford Health System
Hospices Civils de Lyon
Howard Florey Institute
Immune Tolerance Network
Innate Therapeutics
International Multiple Sclerosis Management Practice
Jewish General Hospital Lady David Institute
McGill University
Merck KGaA
Merck Serono
Momenta Pharmaceuticals
Multiple Sclerosis Research Center of New York
Multiple Sclerosis Trust (UK)
Natco Pharma
National Health Service (NHS, UK)
National Institute for Health and Clinical Excellence (NICE, UK)
National Institute of Allergy and Infectious Diseases
National Institute of Neurological Disorders and Strokes
National Institutes of Health Clinical Centre
National Multiple Sclerosis Society (US)
Neurotec Pharma
Northwestern University
Ono Pharmaceutical Co.
Opexa Therapeutics
Oregon Health & Science University
Peninsula College of Medicine and Dentistry, Clinical Neurology Research and Trials Group
Pluristem Therapeutics
Prescription Solutions
Provid Pharmaceuticals
Purdue University
Rush University Medical Centre
Sandoz (part of Novartis)
Santen Pharmaceutical Co
Slavica Biochem
Stem Cell Network (Canada)
Stem Cell Therapeutics
SUNY Downstate Medical Centre
Teva Pharmaceutical Industries
The Gladstone Institutes
UC Boulder
United States National Multiple Sclerosis Society
University of Calgary
University of California Davis
University of California San Francisco
University of Louisville
University of Sao Paolo
Uppsala University
World Health Organization (WHO) 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Telecoms, Energy, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on. 

Please contact Sara Peerun for an exec summary:
Email: sara.peerun@visiongainglobal.com
Tel: +44(0)20-7336-6100
Web: www.visiongain.com


Pharmaceuticals News

November 25 News

will not be displayed